EAM Investors’s Adamas Pharmaceuticals ADMS Stock Holding History

EAM Investors’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-89,585	Closed	-$3.04M	–	389
2017 Q4	$3.04M	Buy	89,585 +4,792	+6%	+$134K	0.54%	47
2017 Q3	$1.79M	Buy	+84,793	New	+$1.55M	0.24%	212
2016 Q1	–	Sell	-141,448	Closed	-$4.01M	–	366
2015 Q4	$4.01M	Buy	+141,448	New	+$2.38M	0.52%	45
2015 Q3	–	Sell	-46,655	Closed	-$1.22M	–	363
2015 Q2	$1.22M	Buy	+46,655	New	+$907K	0.14%	270

Other funds holding ADMS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EAM Investors's ADMS Position: Q1 2018 in Review

EAM Investors sold out of Adamas Pharmaceuticals (ADMS) in Q1 2018, closing a stake of 89,585 shares — an estimated $3.04M sold.

EAM Investors first reported a position in ADMS in Q2 2015 and held it in 4 quarters. The position peaked at $4.01M in Q4 2015. 118 funds tracked by Wall St. Rank hold ADMS as of Q1 2018.

EAM Investors reported no remaining Adamas Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
EAM Investors sold 89,585 Adamas Pharmaceuticals shares in Q1 2018, an estimated $3.04M.
EAM Investors first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 4 quarters.
EAM Investors's Adamas Pharmaceuticals position peaked at $4.01M in Q4 2015.
118 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2018.

Based on EAM Investors's 13F filing for Q1 2018, filed 14 May 2018.